Donate
Suivez-nous sur Linked In
Suivez-nous sur Youtube

Where oncology and autoimmunity converge to accelerate
immunotherapies. CAR‑T cells, Bispecific antibodies, Immune Checkpoint Inhibitors drive Innovations for Patients.
One ambitious objective: to cure autoimmune diseases.

Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

Our Research Targets

INNOVATE

Developing
next-generation
Tools for Experimental
and Clinical
Immunotherapies

Understand

Decoding common
and opposite immune
regulation mechanisms
in Cancer and
Autoimmune Diseases

Treat

Clinical Trials
to test CAR-T
and Bispecific
Antibody Strategies

Teach

Advancing
Education
and Training in
Immunotherapies

Now, CAR‑T cells and Bispecific Therapies offer unprecedented hope with patients achieving lasting remission beyond two years.
FHU CARE² is pioneering this new frontier toward curative immunotherapies.

Prof. Xavier Mariette

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient-centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

Dr. Samuel Bitoun

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

See on

Dr. Camille Bigenwald

“With FHU CARE²,
we harness the power
of CAR T and Bispecific
Therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications

Evolution and prospects for the definition of clinically useful endpoints in Sjögren disease.

Beydon M, Bowman SJ, Seror R.

Curr Opin Oncol. | 2026 Feb;98:102707. doi: 10.1016/j.coi.2025.102707. Epub 2025 Dec 11. PMID: 41385979 Review.

A genetic variant of BAFF is associated with the risk of lymphoma in Sjögren disease.

Beydon M, Dulin M, Ly B, Verstuyft C, Cardoso A, Juge PA, Dieudé P, Lessard CJ, Khatri B, Radziszewski M, Le Guern V, Gottenberg JE, Seror R, Mariette X, Nocturne G.

Ann Rheum Dis. | 2026 Jan 14. doi: 10.1016/j.ard.2025.12.010. PMID: 41539891.

See all Publications